Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:4861570.
doi: 10.1155/2017/4861570. Epub 2017 Oct 3.

Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review

Affiliations

Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review

Marlena Janiczek et al. J Immunol Res. 2017.

Abstract

Prostate cancer treatment is currently based on surgical removal, radiotherapy, and hormone therapy. In recent years, another therapeutic method has emerged-immunological treatment. Immunotherapy modulates and strengthens one's immune responses against cancer. Neoplastic cells naturally escape from the control of the immune system, and the main goal of immune therapy is to bring the control back. Satisfying outcomes after treatment of advanced melanoma and lung cancer suggest a great potential of immunotherapy as an approach for other tumors' treatment, especially in patients primarily introduced to palliative care. After initial clinical trials, immunotherapy seems to have different side effects than chemotherapy. Prostate cancer was the first neoplasm in which a specific vaccine significantly improved survival. There is a tremendous potential for synergistic combinations of immunotherapy with conventional cancer treatments. A combination of several drugs or methods can be a key in radical treatment of metastatic prostate cancer as demonstrated by preliminary studies.

PubMed Disclaimer

References

    1. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cance....
    1. http://www.cancer.org/acs/groups/content/@research/documents/document/ac....
    1. Weiner A. B., Matulewicz R. S., Eggener S. E., Schaeffer E. M. Increasing incidence of metastatic prostate cancer in the United States (2004–2013) Prostate Cancer and Prostatic Disease. 2016;19:395–397. doi: 10.1038/pcan.2016.30. - DOI - PubMed
    1. Ren R., Koti M., Hamilton T., et al. A primer on tumour immunology and prostate cancer immunotherapy. Canadian Urological Association Journal. 2016;10(1-2):60–65. doi: 10.5489/cuaj.3418. - DOI - PMC - PubMed
    1. Wurz G. T., Kao C.-J., DeGregorio M. W. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances Medical Oncology. 2016;8(1):4–31. doi: 10.1177/1758834015615514. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources